Featured

From TCRs to immunotherapy targets: detection of antigens in pediatric brain tumors

Few targetable antigens are known for pediatric brain tumors, which have limited immunotherapy development. Based on this pressing need, Raphael et al. analyzed the TCR repertoires of tumor-infiltrating T cells (TILs), and predicted antigens based...

CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects

Zheng and Qin et al. engineered third-generation CAR T cells targeting TGFβ, and showed that CD4+, but not CD8+ anti-TGFβ CAR T cells (T28zT2 T cells) suppressed tumor growth. Tumor-infiltrating CD4+ ...

PD-1(IR2) promotes tumor evasion via deregulating CD8+ T cell function

Zang et al. found that due to alternative splicing events in tumors, an isoform of PDCD1 retaining the exon 2 PD-L1 binding domain and the second intron (PD-1IR2) was expressed in a variety of human ...

Redirecting immune signaling with cytokine adaptors

To reroute a cytokine’s signaling, Abhiraman et al. generated soluble adaptors comprising units that bind to two sites on a cytokine linked to units that bind to and compel dimerization/activation of ...

Spatial immune scoring system predicts hepatocellular carcinoma recurrence

Jia et al. developed the tumor immune microenvironment spatial (TIMES) score, integrating the spatial expression of five biomarkers (SPON2, ZFP36L2, ZFP36, VIM, HLA-DRB1) to predict HCC recurrence ris...

See all for this week

Previous Digests

Finding the right combination: new insights in anti-PD-1 plus anti-CTLA-4 or anti-LAG3

March 19, 2025

Treatment with checkpoint blockades alone or in various combinations can induce strong antitumor responses, but identifying which treatment or combination will work best for each individual patient is still a challenge. In work recently published in Cancer Cell, Li...

Tumoral RNA splicing: source of neoantigens for off-the-shelf therapies?

March 12, 2025

Immunotherapies targeting tumor-specific antigens (TSAs) derived from somatic mutations have limited potential in tumors with low mutational burdens. A recently discovered source of TSAs are cancer-specific splicing events (neojunctions; NJs), which have the potential to induce CD8+ T cell...

AACR IO 2025

March 5, 2025

The ACIR team attended the newly established AACR IO meeting held on February 23-26, 2025 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

— Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Testimonials